Ensign Group
ENSG Large CapHealthcare · Medical Care Facilities
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Ensign Group en bref
Ensign Group (ENSG) is currently trading at 154,83 € with a market capitalization of 9,0 Md €. The trailing P/E ratio stands at 27.92x, with a forward P/E of 20.83x. The 52-week range spans from 123,04 € to 189,45 €; the current price is 18.3% below the yearly high. Year-over-year revenue growth stands at +17.3%. The net profit margin stands at 6.9%.
💰 Dividende
Ensign Group pays an annual dividend of 0,23 € per share, representing a yield of 0.15%. The payout ratio stands at 4.04%.
📊 Avis des analystes
5 analystes évaluent Ensign Group (ENSG) au consensus : Acheter. L'objectif de cours moyen est de 191,19 €, soit un potentiel de +23.48% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 179,89 € à 199,88 €.
Ensign Group : la thèse d'investissement en détail
Ensign Group (ENSG) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 17.3% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Buy with an average price target implying roughly 23.48% upside from current levels — analyst sentiment is firmly constructive.
À surveiller
- The forward P/E of 20.83x is meaningfully below the trailing 27.92x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 23.48% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Rentabilité élevée des capitaux propres (16.97% ROE)
- Consensus des analystes : Buy
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Ensign Group?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
